O'Donnell J
Rush Medical College, Chicago, Illinois.
Leg Med. 1994:229-67.
Clearly, adverse drug reactions continue to induce injury and harm to patients, despite careful considerations, prescribing, dispensing, and administration. New drugs represent unknown risks and require intense scrutiny and monitoring in their early market stages. Deterioration of good monitoring, selection of more toxic drugs, and poor history taking from patients will continue to present challenges and increased risks from this partially reversible morbidity and mortality to patients.
显然，尽管在用药时经过了仔细的考量、处方、配药和给药，但药物不良反应仍持续对患者造成损伤和伤害。新药存在未知风险，在其上市初期需要严格审查和监测。良好监测的恶化、选用毒性更强的药物以及对患者病史了解不足，将继续带来挑战，并使患者面临这种部分可逆的发病率和死亡率上升的风险。
